Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcellx, Inc. - Common Stock (NQ: ACLX ) 62.56 +0.32 (+0.51%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 296,890 Open 62.42 Bid (Size) 60.00 (20) Ask (Size) 66.38 (1) Prev. Close 62.24 Today's Range 60.61 - 63.23 52wk Range 30.88 - 75.10 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals July 04, 2024 Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. Via InvestorPlace Exposures Product Safety Arcellx Stock Earns Relative Strength Rating Upgrade June 21, 2024 One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. Via Investor's Business Daily Performance YTD +11.42% +11.42% 1 Month +11.48% +11.48% 3 Month +20.31% +20.31% 6 Month +9.95% +9.95% 1 Year +84.16% +84.16% More News Read More The Latest Analyst Ratings For Arcellx June 18, 2024 Via Benzinga Expert Ratings For Arcellx May 31, 2024 Via Benzinga 7 Biotech Stocks to Put on Your Breakthrough Radar May 27, 2024 Via InvestorPlace Analyst Expectations For Arcellx's Future May 14, 2024 Via Benzinga Peering Into Arcellx's Recent Short Interest April 15, 2024 Via Benzinga Arcellx Analysts Boost Their Forecasts After Q4 Results February 29, 2024 Via Benzinga Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know January 04, 2024 Via Benzinga ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program May 09, 2024 From Arcellx, Inc. Via Business Wire Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program May 09, 2024 From Gilead Sciences, Inc. Via Business Wire Arcellx Provides First Quarter 2024 Financial Results May 09, 2024 From Arcellx, Inc. Via Business Wire Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine May 09, 2024 Via InvestorPlace Arcellx to Participate in Two Upcoming Investor Conferences May 07, 2024 From Arcellx, Inc. Via Business Wire Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference April 04, 2024 From Arcellx, Inc. Via Business Wire Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference March 20, 2024 From Arcellx, Inc. Via Business Wire Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley March 07, 2024 Via Benzinga The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 Via InvestorPlace Decoding Bearish Analog And The Warning Signs You Can't Ignore February 07, 2024 Via Talk Markets Topics Stocks Exposures US Equities Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market January 16, 2024 Via InvestorPlace Exposures Product Safety Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 January 04, 2024 Via Benzinga Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development December 15, 2023 Via InvestorPlace Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 12, 2023 Via Benzinga Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say December 11, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.